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ABSTRACT
Introduction: Tumour infiltrating lymphocyte (TIL) based adoptive cell therapy 
(ACT) is a promising treatment for patients with advanced melanoma. Retrospective 
studies suggested an association between previous treatment with anti-CTLA-4 
antibodies and long term survival after subsequent ACT. Thus, we hypothesized that 
treatment with anti-CTLA-4 antibodies can induce favourable changes to be detected 
in TILs. 
Results:  Expanded T cells from Ipilimumab treated patients had a higher 
proportion of cells expressing CD27, intracellular CTLA-4, TIM-3 and LAG-3. In 
addition, broader and more frequent T cell responses against common tumour 
antigens were detected in patients treated with Ipilimumab as compared to anti-
CTLA-4 naïve patients.
Materials and methods: Expanded TILs were obtained from patients with 
advanced melanoma who had received Ipilimumab in the previous six months, or 
had not received any type of anti-CTLA-4 antibody. T cell specificity and expression of 
phenotypic and exhaustion markers were scrutinized as well as functional properties.
Conclusions: Ipilimumab may induce tumor-infiltration of T cells of a more naïve 
phenotype expressing markers related to activation or exhaustion. Additionally, 
Ipilimumab may increase the frequency of T cells recognizing common tumour 
associated antigens.
INTRODUCTION
Throughout the past decade, numerous new 
treatments for metastatic malignant melanoma have 
been tested and proven effective in clinical trials [1]. 
Several of these treatments take advantage of the immune 
system’s ability to eradicate established tumour masses. 
Among these, one of the most promising experimental 
approaches is adoptive cell therapy (ACT), which has 
demonstrated efficacy in several independent clinical trials 
[2–5]. In this approach, tumour infiltrating lymphocytes 
(TILs) are first isolated from a metastasis from the 
individual patient. Thereafter, TILs are activated in vitro 
and massively expanded, and finally transferred back 
intravenously in combination with Interleukin (IL)-2 after 
pre-conditioning with lymphodepleting chemotherapy. 
Even though current ACT protocols have proven to be 
effective, safe and potentially curative treatments for 
metastatic melanoma, the majority of patients eventually 
experience tumour progression, clinical deterioration and 
death [6].
In order to increase the fraction of patients to 
benefit from this treatment, different factors could in 
principle be modulated, including, but not limited to, 
combining ACT with other treatments e.g. targeted 
therapies or immunomodulatory antibodies, with the aim 
of sensitizing the tumour cells or making the T cells more 
functionally competent. Interestingly, a retrospective 
Research Paper
Oncotarget27063www.impactjournals.com/oncotarget
analysis by Rosenberg et al. [6] suggested that prior 
immune checkpoint inhibition with recombinant anti 
CTLA-4 (Cytotoxic T Lymphocyte Antigen 4) antibody, 
followed by progression and thus infusion of TILs, 
was associated with a markedly high five year survival. 
Several rationale explanations of this phenomenon could 
be suggested. Thus, it is possible that anti-CTLA-4 
treatment genuinely increases the response to ACT. 
However, the survival data could also be an artefact due 
to reduced biological aggressiveness of disease in patients 
fit to receive both anti-CTLA-4 antibody treatment and 
subsequent ACT. Therapeutic antibodies targeting CTLA-
4 have been widely tested in clinical trials [7]. Ipilimumab, 
an IgG1 blocking CTLA-4 signaling, was approved for 
the treatment of metastatic melanoma in 2011. This 
antibody works through blockade of an early immune 
checkpoint on T cells, which promotes APC-mediated 
T cell activation and thereby increase T cell specific 
immunity including antitumor immune responses [8]. 
It is also suggested that a contributing (if not essential) 
mechanism is elimination of regulatory T cells (Tregs) [9]. 
In this study, we provide mechanistic insight as to how 
pre-treatment with Ipilimumab may induce measurable 
phenotypic and functional changes of TILs, which may in 
turn explain the increased survival of melanoma patients 
treated with TIL-based ACT who were previously treated 
with Ipilimumab.
RESULTS
Patients
Tumour samples were collected prospectively as 
part of standard-of-care surgery or after enrollment in a 
clinical trial. A total of 34 patients were included in the 
analysis; 15 Ipilimumab naïve and 19 treated within 
6 months prior to tumour removal. Table 1 summarizes 
patient characteristics. As seen, the Ipilimumab naïve 
patients were on average ten years older and had received 
less systemic treatments than the Ipilimumab treated 
patients.
Generation and composition of young TILs 
TIL expansion is accomplished by culturing 
of small tumour fragments in the presence of IL2, 
and young TILs are defined as pooled cultures of 
> 5 × 107 total cells originating from approximately 24 
fragments. Time used for this process varies and could 
theoretically be influenced by several factors. As shown 
in Figure 1A, the duration of time to establish young 
TILs is not affected by prior treatment with Ipilimumab. 
We performed flow cytometric analysis in order to assess 
whether prior treatment with Ipilimumab could affect 
the frequency of CD4+ and CD8+ T cells. Figure 1B 
depicts the frequency of CD4+ and CD8+ T cells. As 
seen, the distribution of these cell subsets varies among 
patients, with a tendency towards a lower frequency of 
CD4+ cells in the Ipilimumab treated group compared 
to the Ipilimumab naïve though the difference was not 
significant. 
Phenotype and exhaustion profile
T cells display a vast repertoire of different surface 
markers that may reflect the functionality of the cell [10]. 
We performed phenotypic analysis on the expanded TILs 
in order to assess whether any markers were consistently 
affected in CD4+ and CD8+ T cell subsets, depending on 
prior Ipilimumab treatment. The expression of selected 
markers may be quantitatively affected by culture 
conditions, most importantly the concentration of IL2 
which may transiently suppress e.g. CD27 expression 
[11]. Therefore, cells were rested for two days in IL2-
free media before analysis. Viability of expanded TILs 
after this resting-step was generally high (Figure 1C).
We assessed the expression of a number of different 
receptors implicated in T cell activation and regulation. 
Results are presented in Figure 2. In general, expanded 
CD4+ and CD8+ T cells displayed a phenotype compatible 
with an activated and/or exhausted phenotype, with 
expression of programmed death receptor 1 (PD-1), B- 
and T-lymphocyte attenuator (BTLA), CD57 and CD28. 
ICOS
The CD28 super family activation marker inducible 
T cell co-stimulator (ICOS) has been linked to a better 
outcome of treatment with Ipilimumab if up-regulated 
during treatment [12]. As seen in Figure 2, the proportion 
of cells expressing ICOS were only modestly higher in 
both CD4+ T cells (median 0.35% Ipilimumab naïve vs. 
0.9% Ipilimumab treated) and CD8+ T cells (median 
0.12% Ipilimumab naïve vs. 0.35% Ipilimumab treated) 
from patients that had been treated with Ipilimumab, 
and the difference was statistically significant only when 
comparing CD4+ T cell subsets (p = 0.035 for CD4+ T and 
p = 0.5 for CD8+ T).
CD27
CD27 is expressed on T cells giving rise to memory 
responses [13], and expression of CD27 in T cells used 
for ACT confers a higher likelihood of a clinical response 
[6]. As seen, both CD8+ and CD4+ T cells from patients 
that had received Ipilimumab uniformly demonstrated 
higher frequencies of CD27+ cells (p = 0.03 for CD4+ and 
p = 0.003 for CD8+). Expression was in general absent 
or diminutive in CD8+ T cells from Ipilimumab naïve 
patients, whereas a small proportion of CD4+ T cells 
displayed expression. In general, CD8+ T cells had higher 
frequencies of CD27+ cells, compared to CD4+ T cells. 
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CTLA-4
CTLA-4 is an important regulator of T cell function 
and reactivity, especially during priming of immune 
responses [14]. Ipilimumab targets CTLA-4 and is 
likely to have effect on the dynamics of this molecule. 
We analyzed the level of expression on the surface and 
total expression (surface + intracellular) of CTLA-4. As 
seen from Figure 2 (2nd line from the top), the surface-
expression of CTLA-4 is generally low in both CD4+ 
T cells and CD8+ T cells. There was a trend towards a 
higher surface expression in CD4+ cells from Ipilimumab 
treated patients, however non-significantly (p = 0.2). 
When comparing total expression of CTLA-4, i.e. the 
positive fraction in permeabilized cells, in Ipilimumab 
naïve and treated, we found uniformly higher expression 
in both CD4+ and CD8+ cells from patients treated with 
Ipilimumab (p = 0.005 and p = 0.02, respectively).
TIM-3
TIM-3 is an immune inhibitory molecule first 
identified as a regulator of Th1 cells [15] and implicated 
in T cell dysfunction in chronic HIV infection [16] 
and in TILs from melanoma patients [17]. There was a 
significant trend towards higher proportion of CD4+ T 
cells expressing TIM-3 (p = 0.016) in Ipilimumab treated 
patients. In CD8+ T cells, expression of this antigen was 
higher in patients treated with Ipilimumab compared to 
untreated, however not statistically significant (median 
14.3% vs. 31.8%, Mann-Whitney test p = 0.06).
LAG-3
Lymphocyte-activation gene 3 (LAG-3) is up-
regulated on T cells upon activation, and functions as a 
regulatory protein, preventing signaling through CD3, when 
interacting with its receptor HLA class II [18]. In a murine 
model, LAG-3 has been shown to mediate tumour immune-
escape through tolerance [19], and synchronous knock-out 
of LAG-3 and PD-1 confers resistance to tumour xenografts 
[20]. We found a significantly higher median expression 
of LAG-3 in CD8+ T cells from patients treated with 
Ipilimumab compared to Ipilimumab naïve, mean 9.9% vs. 
37.95%, (student T test p = 0.001). We found no significant 
difference in LAG-3 expression in CD4+ T cells (p = 0.06).
Table 1: Patient demographics
 Ipilimumab naïve Ipilimumab within 6   months
Number of patients 15 19
Mean age at resection (SD) 56.8 (10) 50.3 (13)
No. Ipilimumab treatments
2 0 2
3 0 1
4 0 16
Number of systemic treatments (SD) 0.5 (0.7) 1.9 (1)
Temozolomide 1 1
Vemurafenib 0 2
IL2 5 13
ACT 1 0
DC vaccination 0 1
Ipilimumab 0 19
Disease stage
IIIc 1 1
M1a 2 3
M1b 1 0
M1c 11 15
Trial
Clinical trial 11 19
Research protocol 4 0
Gender: male/female 5/10 9/10
Patient demographics at the time of tumour removal for T cell culture. Abbreviations: SD (standard deviation) IL2 
(interleukin 2) ACT (adoptive cell therapy) DC (dendritic cell).
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CD8+ and CD4+ T cell anti-tumour reactivity
Our group recently reported that T cell reactivity 
towards autologous and allogeneic melanoma cell lines is 
positively correlated to treatment response in TIL based 
ACT [5], that Ipilimumab has been shown to induce influx 
of T cells in tumour lesions in patients with clinical benefit 
[22] and might have an impact on T cell reactivity towards 
tumour cells. T cell reactivity in terms of cytokine and 
CD107a production upon co-culture with autologous 
cancer cell lines using intracellular cytokine staining 
and flow cytometry analysis was assessed. Cancer cells 
were treated with IFN-γ before co-culture in order to up-
regulate antigen presenting machinery  [21]. T cells were 
deemed tumour reactive when positive for either CD107a, 
IFN-γ or TNF-α or a combination of these (see methods 
section). Though the median level of reactivity in CD8+ 
T seemed slightly lower in TILs from Ipilimumab treated 
patients (p = 0.5), the sample size and level of difference 
does not allow firm conclusions to be drawn in terms of 
reactivity against autologous tumour cells. Results are 
presented in Figure 3A. 
Antigen specificity 
We performed combinatorial coding with MHC 
class I tetramers and flow cytometric analysis in order to 
assess the frequencies of specific melanoma-associated 
antigen-specific cells among the TILs [23]. Samples 
were screened for specificity against a panel of 175 
HLA-A2 restricted melanoma associated T cell epitopes 
from published tumour associated antigen [24]. Prior to 
analysis, patient samples were HLA typed, and antigen 
specificity was assessed with HLA-matched tetramers. 
Only HLA-A2+ patients were included in these analyses, 
and only epitopes towards which at least one patient 
harbor immune responses are included in the figures. 
Results are presented in Figure 3B–3C and Table 2. 
In general, we found frequent responses towards shared 
tumour antigens. The heatmap in Figure 3B illustrates that 
responses were generally broader and more frequent in 
Ipilimumab treated patients as evident by purple colours. 
As seen in Figure 3C, a tendency for higher frequency 
of responses towards common tumour antigens was 
detected in Ipilimumab treated patients, and the average 
size of a response tended to be higher after Ipilimumab 
treatment. The differences between the two groups for 
both parameters were not statistically significant (p = 0.2 
for both), but the sample size in these experiments is not 
suitable for formal hypothesis testing. 
DISCUSSION
In this work, we investigated whether Ipilimumab 
induces measurable changes on phenotype, antigen 
specificity, and functionality of (expanded) tumour-
infiltrating T cells. Samples were collected prospectively 
from patients receiving standard of care surgical resection 
of tumor metastases (mostly for palliative reasons) or for 
enrolment in ACT trials. 
In general, we found high expression of markers 
traditionally regarded as immune inhibitory molecules 
including PD-1, BTLA, LAG-3 and TIM-3. Additionally, a 
high proportion of both CD4+ and CD8+ T cells expressed 
CD28, associated with an early or intermediate phenotype of 
the TILs [25]. To our knowledge, it is not well established to 
what extent the culture process used for generating T cells for 
current ACT protocols affects the phenotype or functionality 
Figure 1: Young TIL generation, CD4/CD8 phenotype and cell viability. (A) Days to establish young TIL i.e. duration from 
initiation of T cell culture until the total cell count reaches > 50 × 106 sorted according to whether the patient had received Ipilimumab prior 
to tumour removal. (B) Percentage of T cells expressing CD4 or CD8 in the expanded TILs sorted according to whether the patient had 
received Ipilimumab prior to tumour removal. (C) Proportion of lymphocytes not staining positive for the dead cell marker Near Infra-Red, 
after resting of expanded TILs in IL2 free media.
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of TILs, though we recently reported that the relative 
distribution of T cells expressing known antitumor functions 
seems maintained at stable levels [26]. Several groups have, 
however, reported that the tumour microenvironment induces 
T cell unresponsiveness towards tumour cells, which is 
apparent by high T cell expression of inhibitory markers [17], 
[20],  [27], which could point to a similarity between the 
phenotype of tumour infiltrating lymphocytes in vivo and after 
expansion in vitro. On the other hand, the rapid expansion 
protocol includes culture conditions delivering stimuli 
far exceeding physiologic activation, which might induce 
homeostatic expression of inhibitory molecules on its own. 
Table 2: T cell specificity of expanded tumour infiltrating T cells
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Mart-1 EAA 0.04 0.6 2.9  0.003 0.006 4.1
Mart-1 Aag 0.1 1.5  
gp100 AML 0.008 0.008  
gp100 YLE 2.5 1.8 0.03 0.03  0.03
gp100 IMD 0.022 0.1 0.4  
gp100 ITD 0.005 0.3 0.01  
gp100 VLY 0.04  
Tyrosinase CLL   0.8         0.3
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MAGE-A8 KVA 0.03  
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MG50 LLL 0.04 0.04  0.03
MG50 TLK 2.1 2.2  0.001
Meloe-1 TLN 0.01 0.03  
Telomerase RLF  0.1
KIF20a CIA   0.006      0.004    
T cell specificity of expanded tumour infiltrating T cells assessed with combi coding. Green background indicates patients had 
received Ipilimumab up to six months before tumour removal. Red background indicates Ipilimumab naïve patients. Numbers 
indicate the percentage of CD8 T cells staining positive for a MHC/peptide tetramer loaded with the given peptide antigen. 
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We found that several phenotypic markers were 
affected by administration of Ipilimumab prior to surgical 
removal of tumor samples used to isolate and expand 
TILs, suggesting that Ipilimumab induced marked changes 
in T cell infiltrates, which can still be detected despite 
heavy in vitro expansion. This is particularly striking, 
as Ipilimumab was administered relatively short before 
tumor removal and the in vitro process involved several 
Figure 2: Phenotype- and exhaustion markers. Proportion of expanded tumour infiltrating T cells expressing the depicted markers 
were compared between patients treated with Ipilimumab before removal of tumour and patients naïve to anti-CTLA-4 treatment. 
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rounds of expansion, which may presumably take several 
months or years in a comparable in vivo physiological 
setting. Of note, clinical responses induced by Ipilimumab 
may last for over a decade [28], thus it is not surprising 
that measurable changes in immune parameters can be 
detected despite harsh manipulation.
Surface expression of the inhibitory receptor 
CTLA-4,which is targeted and neutralized by Ipilimumab, 
were generally absent on T cells from both groups of 
patients. However, upon permeabilization of the cell 
membrane our analysis revealed high intracellular 
expression of this antigen and Ipilimumab treatment 
appeared to be associated with higher frequencies of 
CTLA-4+ cells in both the helper and cytotoxic T cell 
compartments. The implication of this is not known, 
but may reflect a physiologic counter regulation upon 
treatment with anti-CTLA-4 antibody. Interestingly, 
higher pre-treatment levels of intracellular CTLA-4 
has been associated with a better overall survival in 
prostate cancer patients treated with Ipilimumab [29]. 
Several articles have reported ICOS up-regulation during 
treatment with Ipilimumab, as a strong correlate with 
subsequent clinical response [29], [30]. Up-regulation of 
this activation marker may be evident long after treatment 
discontinuation [31], and a recent publication has 
indicated that the ICOS+ T cells may be the actual effector 
cells conveying the anti-tumour effect of Ipilimumab in a 
murine model [32]. We scrutinized whether Ipilimumab 
affected surface expression of ICOS on T cells. Indeed, 
we found only a very low fraction expressing ICOS 
with a slightly higher expression in CD4+ T cells in the 
Ipilimumab treated group. No significant difference was 
demonstrated in CD8+ T cells, which is in accordance 
with a more pronounced effect of Ipilimumab on ICOS 
expression on the CD4+ T cell compartment [31]. 
Furthermore, expression of TIM-3 and LAG-3 were 
significantly higher in CD8+ T cells from patients 
treated with Ipilimumab, and with regard to the former, 
borderline significantly higher in CD4+ T cells. LAG-3 is 
an inhibitory molecule with structural similarity to CD4, 
which, upon binding by its ligand MHC class II, associates 
with the CD3/T cell receptor (TCR) complex and reduces 
signal-strength through the TCR thereby inhibiting 
proliferation and cytokine response [18, 33]. It has been 
Figure 3: T cell reactivity and specificity. Reactivity of expanded tumour infiltrating T cells was tested in a co-culture assay with 
autologous cancer cells and assessed with intracellular cytokine staining. T cell specificity was measured using combi coding with MHC 
tetramers loaded with a panel of tumour antigen derived peptides in HLA-A2 + patients. Patients treated with Ipilimumab were compared 
with patients naïve to anti-CTLA-4 treatment. (A) T cell reactivity against autologous cancer cells in CD4+ (top) and CD8+ (bottom) T cells. 
(B) Heat map representing row Z-score for HLA-A2 restricted T cell responses found in 12 HLA-A2+ patients. Patients left of the black 
line had received Ipilimumab prior to removal of tumour whereas patients depicted on the right of the line were anti-CTLA-4 treatment 
naïve. (C) Top: sum of frequencies of T cells with specificity against common tumour antigens. Bottom: average size of a T cell response.
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implicated as an important mediator of tumour immune 
escape in melanoma [34], and a neutralizing antibody 
developed by Bristol-Myers Squibb is currently being 
tested in combination with Nivolumab (clinicaltrials.gov 
identifier NCT01968109). TIM-3 also functions as an 
immune inhibitory receptor specifically expressed on Th1 
and Tc1 inflammatory cells [15], which may induce cell 
death when engaging its ligand galectin-9 [35]. However, 
signaling through this receptor is highly complex, and cells 
may be salvaged from galectin-9/TIM-3 induced apoptosis 
by expression of the intracellular signal-repressor Human 
Leucocyte Antigen B-associated transcript 3 [36], making 
interpretation of TIM-3 expression ambiguous. The 
underlying mechanism for the observed up-regulation 
of LAG-3 and TIM-3 is not clear, though it could be 
speculated that Ipilimumab, by blocking the effect of an 
important regulatory molecule on T cells, induces counter 
regulatory homeostatic mechanisms. Another possibility 
is that Ipilimumab attracts highly activated T cells to 
the tumour, which are likely to express a variety of both 
regulatory and inflammatory markers. 
Response towards autologous tumour cells 
displayed a trend towards lower reactivity in Ipilimumab 
treated patients, though not significantly. However, 
Ipilimumab induces an influx of cells with a more naïve 
phenotype into the tumour microenvironment [32], which 
may not be capable of producing cytokines without 
further differentiation [10] and can be especially evident 
in short-term in vitro assays providing temporary limited 
stimuli. Despite this, the cells may in fact be tumour 
specific and reactive after activation and proliferation. 
In accordance with this, we found a markedly higher 
proportion of both CD4+ and CD8+ T cells expressing 
CD27, which is associated with a more naïve phenotype 
and longer telomere length [6]. CD27 expression was 
generally very low or even absent when analyzing 
cells right after rapid expansion, where cells have been 
exposed to very high concentrations of IL2. We thus 
confirm data from Huang et al. [11] demonstrating that 
a subset of T cells will re-express CD27, and possibly 
other markers, when withdrawn from supra-physiologic 
cytokine concentration. The higher proportion of CD27+ 
T cells in Ipilimumab treated is notable for several 
reasons; it indicates that Ipilimumab has long lasting 
impact on T cell dynamics, which will be evident even 
after extended culture and expansion. Additionally, 
this marker is associated with a higher chance of 
engraftment upon transfer into patients, which, in turn, 
is associated with better clinical outcome of ACT [6]. 
Taking advantage of the combinatorial coding technique, 
we screened expanded cells for reactivity towards 
a library of epitopes from shared tumour associated 
antigens. In order to compare data between patients, 
only HLA-A2 positive patients were included in the 
analyses. The analyses suggest that responses were 
less frequent and had specificity against fewer different 
epitopes in Ipilimumab naïve patients. This finding may 
suggest that a higher fraction of adoptively transferred 
T cells is genuinely tumour specific, but this was not 
directly supported by functional data on reactivity 
against autologous cancer cell lines. However, cancer 
cells used in these assays may not fully represent the 
whole complexity and heterogeneity of an in vivo 
growing tumor. Other factors, including antigen loss or 
down-regulation of antigen processing and presentation 
machinery may influence the antitumor reactivity, as well 
as a more naïve phenotype may influence the frequency 
of true tumor-specific cells able to generate measurable 
immune responses in short-term assays. This means 
that our functional assays may actually underestimate 
the proportion of tumour specific T cells depending on 
the individual characteristics of the autologous tumor 
cell line.
Interestingly, Kvistborg et al. [37] found broadened, 
but not increased, magnitude of tumor-antigen specific 
T cell responses in the peripheral blood of patients treated 
with Ipilimumab.
The epitope-library used in our specificity screening 
is vastly derived from shared tumour associated antigens, 
and hence a significant fraction of genuine tumour specific 
T cells may be missed. It has previously been shown that 
TILs may be neoantigen-specific [38, 39], and previous 
work from our group has demonstrated that only a small 
fraction of the expanded T cells can be accounted for in 
terms of specificity [24]. Despite this, our findings still 
indicate that responses towards tumour associated antigens 
were more frequent and broader in Ipilimumab treated 
patients.
It should be kept in mind that patients in the 
Ipilimumab group were referred to surgical tumour 
resection and ultimately ACT because they lacked 
disease control after check point inhibition. Consequently 
our findings do not necessarily reflect TIL phenotype and 
tumour reactivity in clinical responders to Ipilimumab. 
However, these patients do indeed represent relevant 
candidates for TIL based ACT. In conclusion, we 
have identified several T cell-related factors impacted 
by prior treatment with Ipilimumab. Especially the 
higher expression of CD27, which has been linked to 
better outcome of ACT, supports a beneficial effect of 
Ipilimumab before harvest and expansion of tumour-
infiltrating lymphocytes. A phase I clinical study 
(clinicaltrials.gov identifier NCT01988077) conducted at 
the Sheba Medical Center, Israel, is currently assessing 
response rate and evaluating toxicity in a trial combining 
Ipilimumab with ACT. This study will give indications 
as to whether the combination is appropriate in a 
prospective trial. Outcome in such a trial may be even 
better than estimated from the retrospective analysis 
published by Rosenberg et al [6], given that patients 
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treated with Ipilimumab in our study were selected for 
ACT because they did not experience disease control 
with Ipilimumab. 
MATERIALS AND METHODS
Patients and tumour specimens 
All procedures were approved by the Scientific 
Ethics Committee for the Capital Region of Denmark. 
Written informed consent was obtained from patients before 
any procedure according to the Declaration of Helsinki. 
Metastatic tumour specimens of at least 1cm3 were obtained 
from patients with melanoma stage IV undergoing standard-
of-care surgical procedures as part of a research protocol 
approved by the local ethics committee (approval no. H-2-
2014-052) or from specimen collection for enrollment in a 
clinical trial (Clinicaltrials.gov Identifier: NCT 00937625). 
Only patients either treated with Ipilimumab within six 
months prior to tumour removal or patients that were anti-
CTLA-4 naïve were included in the study. As a consequence 
of this study design, patients in the Ipilimumab group 
were selected based on treatment failure to Ipilimumab. 
Part of the samples used in this publication, have also been used 
for analyses in previously published studies [5, 21, 24, 40–41].
Fresh specimens were immediately transported to 
the laboratory in cell media (RPMI 1640). The tumour 
masses were isolated from the surrounding tissues, and 
tumours were sliced into multiple fragments (1–3 mm3 
each) with a scalpel.
Reagents and cells for TIL and autologous 
tumour generation. 
Human AB serum (HS) was purchased from 
Sigma- Aldrich (Brøndby, Denmark); RPMI-1640 with 
GlutaMAX and AIM-V medium were obtained from 
Invitrogen (Nærum, Denmark). RhIL2 (Proleukin) was 
from Novartis (Basel, Switzerland), and OKT3 (anti-CD3) 
antibody was from Cilag AG (Schaffausen, Switzerland). 
Pulmozyme was purchased from Roche (Basel, 
Switzerland). Allogeneic peripheral blood mononuclear 
cells (PBMCs) (or feeder cells) were obtained from buffy 
coats from healthy donors. Solu-Cortef (hydrocortisone 
sodium succinate) was obtained from the local hospital 
pharmacy. Fetal bovine serum (FBS) was from Gibco 
(Nærum, Denmark). Complete medium (CM) consisted of 
RPMI-1640 with GlutaMAX, 25 mM HEPES pH 7.2, 100 
U/ml penicillin, 100 µg/ml streptomycin and Fungizone® 
(Bristol-Myers Squibb, New York, NY, USA) 1,25 lg/ml 
supplemented with 10% HS and 6000 IU/ml of rhIL2. 
Rapid expansion medium (RM) consisted of AIM-V 
medium and Fungizone® 1,25 lg/ml supplemented with 
6000 IU/ml rhIL2. 
TIL generation and melanoma culture generation 
Young TIL cultures were generated from tumour 
fragments cultured in IL2-containing culture medium, as 
previously described [42–44]. Briefly, on day 0, individual 
tumour fragments were placed in the wells of a 24-well 
plate with 2 ml of CM per well. Cell cultures were kept 
in a humidified atmosphere at 37°C, with 5% CO2 in air. 
Cell density and morphology were assessed every other 
day. Within one week after initiation of the culture, half of 
the culture media was carefully aspirated and replaced with 
fresh. This was subsequently repeated three times per week. 
Young TILs were defined as pooled cultures of at least 5 × 
106 total cells originating from approximately 24 fragments 
that had expanded to confluent growth of the original 2-ml 
wells and eliminated adherent tumour cells. The definition 
of young TILs is based on the minimum cell number that 
would be needed for therapeutic protocols according to 
previously published studies [2, 43–47] and our internal 
experience. Autologous melanoma cultures were established 
from additional tumour fragments or from transport media 
from the same metastatic lesions, and cultured in RPMI 
1640 supplemented with 10% FBS and 500 ng⁄ml of Solu-
Cortef for inhibition of lymphocyte proliferation. 
Rapid expansion protocol
Cryopreserved or freshly prepared TILs were 
expanded in a 14-day Rapid Expansion Protocol (REP). 
Briefly, cultures were initiated in upright T175 flasks 
(Nunclon, 1 × 106 TILs) or T25 flasks (1 × 105 TILs) in 
standard culture medium supplemented with stimulating 
anti-CD3 antibody, allogeneic gamma irradiated peripheral 
blood mononuclear feeder cells in a ratio of 200:1 TILs 
and high doses of interleukin-2, as described previously 
[40]. On day 7, TIL cultures were either continued in the 
Wave bioreactor system, as previously described [48], or 
in static conditions [40]. Cells were allowed to proliferate 
for a total of 14 days according to the REP, after which 
cells were cryo-preserved in 90 % human AB serum with 
10% dimethyl sulphoxide (Herlev Hospital Pharmacy) 
until further analysis.
Exhaustion profile analysis
Cells were thawed and cultured in AIM-V culture 
medium with 5% heat-inactivated human serum in 24-
well plates at a concentration of 3–5 × 106 cells/ml. Plates 
were incubated in a humidified incubator at 37°C, with 
5% CO2. After 48 hours of resting, cells were harvested 
and washed in FACS buffer before surface staining.  For 
exhaustion profile analysis, cells were stained at 4°C for 
30 min., washed, and, for tubes only intended for surface 
staining, resuspended in FACS buffer. For tubes intended 
Oncotarget27071www.impactjournals.com/oncotarget
for intracellular staining, cells were permeabilized using 
BD Bioscience Cytofix/CytopermTM Kit according to 
manufacturer’s instructions. The following antibodies were 
used: CD4-PerCP, CD57-FITC, CD27-PE, CD56-PE-
Cy7, CD28-APC, CD8-AmCyan, ICOS-PE, BTLA-PE, 
CTLA-4-APC, PD-1-PE-Cy7 (all from BD Bioscience, 
San Jose, CA, USA), Near Infra Red dead cell marker 
(Dako), LAG-3-FITC (LifeSpan Biosciences), TIM-3 
(eBioscience), CD107a; PECy7-conjugated IFN-c; PerCP-
conjugated CD8; APC-conjugated CD4, TNF-a; APCCy7-
conjugated CD3. Cells were resuspended in FACS buffer 
prior to acquisition, and the cells were acquired using a 
BD FACSCanto II flow cytometer. A minimum of 100 000 
events were recorded per sample. Analysis was performed 
with the BD FACSDiva Software (BD Bioscience,)
Anti-tumour activity of TILs and FACS analysis 
of melanoma cells 
For simultaneous CD107a and intracellular cytokine 
analysis, TILs were cultured for 5 hours at 37°C with 5% 
CO2 in air in the presence or absence (negative control) 
of autologous cancer cells at an effector/target (E:T) ratio 
of 3:1, as previously described [40]. Autologous cancer 
cells used as target cells were pretreated with 100 IU/ml 
interferon (IFN) g for 72 hours. Cells were acquired using 
a BD FACSCanto II flow cytometer (BD, Albertslund, 
Denmark). At least 200,000 live TILs were acquired. 
Analysis was performed with the BD FACSDiva Software. 
Criteria to define a positive anti-tumour response were as 
follows: a frequency of CD107a or cytokine positive TILs 
of at least twice the frequency of the background and at 
least 50 positive events; otherwise, at least 10 times the 
background. Cells were deemed tumour reactive when 
positive for either CD107a, IFN-g or tumour necrosis 
factor (TNF) α or a combination of these.
Major histocompatibility complex (MHC) 
multimer-based analyses of antigen specific T cells
The generation of combinatorial encoded MHC 
multimers and the gating strategy is described in detail 
by Hadrup et al. [49, 23]. MHC multimers were produced 
using conditional ligand exchange technology, for the 
HLA ligands HLA-A1, A2, A3, A11 and B7 [50, 51]. For 
detection of antigen-specific T cell populations we made 
use of combinatorial encoding with MHC multimers, in 
brief, peptide-MHC monomers were multimerized with 
two different fluorescence-labeled streptavidin conjugates 
for each peptide specificity, enabling the simultaneous 
testing of 28 different specificities in a single sample 
by combining 8 colors into dual-color codes for MHC 
multimers, in order to measure specific T cell populations 
with flow cytometry. The cells were additionally stained 
with LIVE/DEAD® Fixable Near-IR Dead Cell Stain 
Kit for 635 nm excitation (Invitrogen, Life Technologies, 
Naerum, Denmark), CD8-Alexa Flour 700 (BD 
Pharmingen, Albertslund, Denmark) or CD8-peridinin 
chlorophyll (PerCP) (Invitrogen, Life Technologies, 
Naerum, Denmark) and fluorescein isothiocyanate (FITC) 
coupled antibodies to CD3 or to a panel of CD4, CD14, 
CD16, CD19 (all from BD Pharmingen, Albertslund, 
Denmark) and CD40 (AbD Serotec, Puchheim, Germany). 
Data acquisition was performed on an LSR II flow 
cytometer (Becton Dickinson) with FacsDiva software. 
Positive responses were defined by a minimum of 10 
events at a frequency of minimum 0.002% of CD8 T cells. 
We used streptavidin conjugated fluorochromes: Qdot- 
585(Q10111MD), 605 (Q10101MD), 625 (A10196), 655 
(Q10121MD), 705 (Q10161MD) all from Invitrogen and 
PE-Cy7 (405206), APC (405207) and PE (405203) from 
Biolegend to encode the specific MHC multimers. MHC 
multimers were prepared at 100ug/ml and cells were 
stained using 2ul of each double colored MHC multimer. 
First, we gated on lymphocytes followed by single cells, 
live cells, and CD8 cells. Gates were made for each 
single MHC multimer color and then combined to gate 
out events positive for only one MHC multimer color 
and three or more MHC multimer colors, while showing 
events positive for exactly two MHC multimer colors.
Statistics
Box plots show the median (horizontal line) inside 
a box spanning the 25th to the 75th percentile. Whiskers 
extend 1.5 times the interquartile range or, if no case has a 
value in that range, to the minimum or maximum values. 
A horizontal line in dot plots represents the median. Data 
were analyzed using SPSS software (Version 19.0, IBM 
Cooperation, Somer, NY, USA). Graphs were made 
using SPSS software or GraphPad Prism 5 (GraphPad 
Software, La Jolla, CA). The heatmap was prepared 
using Rstudio statistical software (Version 0.98.507–© 
2009–2013 RStudio, Inc.) with the program package 
heatmap.2. Color codes in the heat map represent row 
Z-score calculated as (x–μ)/σ, where x is the measured 
value, μ is the mean value for all observations in the 
row and σ is the standard deviation of the row. Data is 
represented without clustering. In this figure, a negative 
value equal to the average size of responses towards 
the given antigen was assigned for a given specificity, 
if the patient did not mount a response towards the 
epitope in question in order to distinguish low frequency 
responses from complete absence of a response. 
Between-group differences of data on an interval scale 
were evaluated using Mann–Whitney U-test or students 
T test when applicable. All tests were performed two-tailed 
and a P value of 0.05 or below was considered significant. 
No correction for multiple comparisons was performed in 
this exploratory study. 
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